Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation Released On 15th January 2015
Summary Large Degree of Innovation in Parkinsons Disease Pipeline The Parkinsons disease (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market relies on symptomatic treatments that target neuromodulatory receptors, the pipeline shows a diverse range of neuroprotective therapies targeting dysfunctional disease processes. This diversity is partially due to the presence of 90 first-in-class products, which accounts for 37% of the overall pipeline therapies that disclosed their target. In an industry, market and development landscape that favors first-in-class over non-first-in-class development in many ways, such as through faster approval or greater revenue, this finding has strategic implications for a wide array of market participants, both large and small. Despite their historically high attrition rate, first-in-class therapies that reach the market have the potential to transform and improve the PD treatment landscape. Alignment of First-in-Class Molecular Target with Disease Processes and Genetics PD is a complex and multifaceted disease with a complex interplay between different pathological processes. Enormous research efforts and significant technological advances JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
have furthered knowledge of the neuroanatomy of the basal ganglia and of the fundamental processes underlying neurodegeneration, helped by the ongoing identification of susceptibility genes and causative genes in familial PD. Although the exact mechanisms that initiate onset remain unclear, these insights have been translated into the pool of novel therapeutic targets, which may potentially become disease-modifying therapies by aligning to the disease processes and some genetic determinants of PD. GBI Researchs proprietary analysis showed substantial variation in how well the functional roles of PD first-in-class targets align to the pathophysiology of PD. Further in-depth analysis identified the most promising first-in-class targets based on various scientific and clinical parameters. Examining scientific and clinical data of promising first-in-class targets showed that first-in-class status is not, in its own right, enough for a successful product; however, the first-in-class products substantiated by scientific and clinical evidence will be exciting future Browse complete Report on: http://www.jsbmarketresearch.com/healthcare-medical/r-frontier-pharmaparkinsons-disease-identifying-and-commercializing-first-in-class-innovation151420 prospects with the potential to transform the PD market.
First-in-Class Products in Licensing and Co-development Deals Strategic consolidation is relatively uncommon in the PD market. Concerning first-in-class specifically, only nine first-in-class products that are currently in development have been involved in licensing or co-development deals since 2006. Despite the low sample size, it is clear that the first-in-class PD products offer an attractive investment prospect as they command much higher deal values and, on average, deals occur earlier in development compared to non-first-in-class counterparts. Both trends were substantiated by industrywide data that showed that, particularly in Phase I, first-in-class products would attract larger mean and median total deal values. The data highlight that the first-in-class deals JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
landscape is different and indicates a greater chance of becoming much more lucrative than the deals landscape for addition-to-class or advance-in-class therapies. A total of 81 first-in-class products that are currently in development have not yet been entered into a licensing or co-development deal. Under a growing unmet need for diseasemodifying therapies and increasing understanding of disease processes allowed by technological advances, there are numerous opportunities for strategic alliances to bolster a first-in-class portfolio or fund clinical development. Some of these first-in-class products are supported by promising scientific and clinical data, making them attractive prospects as both therapeutics and investment opportunities. Scope The Frontier Pharma: Parkinsons Disease - Identifying and Commercializing Firstin-Class Innovation report analyzes innovation in PD in the context of the overall pipeline and current market landscape. It also analyzes the deals landscape surrounding first-in-class products and pinpoints in-licensing opportunities.The report includes A brief introduction to PD, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms Coverage of the changing molecular target landscape and particular points of innovation in the pipeline A comprehensive review of the pipeline for first-in-class therapies, analyzed by stage of development, molecule type and molecular target Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews of novel molecular targets Industry-wide analysis of first-in-class deals compared to non-first-in-class deals An assessment of the licensing and co-development deal landscape for PD therapies and benchmarking of deals comparing first-in-class and non-first-in-class-products Reasons to buy The report will enable business development and enable marketing executives to strategize their product launches by allowing them to Understand the focal shifts in molecular targets in the PD pipeline Understand the distribution of pipeline programs by phase of development, molecule type and molecular target JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
Access a scientific and clinical analysis of first-in-class developmental programs for PD, benchmarked against non-first-in-class targets Assess the valuations of licensed and co-developed PD treatments Access a list of the first-in-class therapies potentially open to deal-making opportunities Table of Contents 1.1 List of Tables 3
1.2 List of Figures 3 2 Executive Summary 5 2.1 Highly Innovative and Diverse Pipeline 5 2.2 Alignment of Innovation to Disease Processes and Genetics 5 2.3 Deals Landscape Present Substantial Investment Opportunities 5 3 The Case for Innovation 6 3.1 Growing Opportunities for Biologic Products 7 3.2 Diversification of Molecular Targets 7 3.3 Innovative First-in-Class Product Developments Remain Attractive 7 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8 3.5 Sustained Innovation 8 3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10 4.1 Epidemiology 10 4.2 Disease Etiology 11 JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
4.2.1 Exposure to Environmental Toxins 11 4.2.2 Genetic Causes of Familial Parkinsons Disease 11 4.2.3 Susceptibility Genes for Parkinsons Disease 13 4.3 Disease Pathophysiology 13 4.3.1 Basal Ganglia Anatomy and Physiology 13 4.3.2 Processes Underlying Neurodegeneration in Parkinsons Disease 16 4.4 Disease Symptoms 20 4.5 Co-morbidities and Complications 20 4.6 Diagnosis 21 4.6.1 Classification 21 4.7 Prognosis and Disease Staging 23 4.8 Treatment Options 24 4.8.1 Pharmacological Treatment 24 4.8.2 Non-pharmacological Treatments 28 4.9 Marketed Product Overview 28 4.10 Overview of Marketed Products for Parkinsons Disease 29 4.11 Efficacy and Safety of Marketed Products 31 4.12 Treatment Algorithm 33 4.13 Current Unmet Needs 35
JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
5 Assessment of Pipeline Product Innovation 37 5.1 Parkinsons Disease Pipeline by Molecule Type, Phase and Therapeutic Targets 37 5.2 Comparative Distribution of Programs between the Parkinsons Disease Market and Pipeline by Therapeutic Target Family 41
6 Signaling Network, Parkinsons Disease Genetics and Innovation Alignment 46 6.1 The Complexity of Signaling Network in Central Nervous System 46 6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 47 6.3 First-in-Class Target Matrix Assessment 51 7 First-in-Class Target and Pipeline Program Evaluation 54 7.1 Overview of Pipeline Programs Targeting -synuclein 54 7.2 Overview of Pipeline Programs Targeting LRRK2 57 7.3 Overview of Pipeline Programs Targeting Glial Cell-Derived Neurotrophic Factor 60 7.4 Overview of Pipeline Programs Targeting Progranulin 63 7.5 Overview of Pipeline Programs Targeting Cerebral Dopamine Neurotrophic Factor 66 7.6 Overview of Pipeline Programs Targeting Mesencephalic Astrocyte-Derived Neurotrophic Factor 68 7.7 Overview of Pipeline Programs Targeting Tyrosine Receptor Kinase B 70 7.8 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 73 7.9 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 8 75 JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
7.10 Overview of Pipeline Programs Targeting C-jun-N-Terminal Kinases 76 7.11 Overview of Pipeline Programs Targeting DJ-1 79 7.12 Overview of Pipeline Programs Targeting Reactive Oxygen Species 80 7.13 Overview of Pipeline Programs Targeting Heat Shock Transcription Factor 1 82 7.14 Overview of Pipeline Programs Targeting Heat Shock Protein 90 84 7.15 Overview of Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 86 7.16 Overview of Pipeline Programs Targeting Protein Phosphatase 2A 88 7.17 Overview of Pipeline Programs Targeting Cytochrome P450 2D6 90 7.18 Conclusion 91 8 Deals and Strategic Consolidations 93 8.1 Industry-wide First-in-Class Deals 93 8.2 Parkinsons Disease Deals Landscape 95 8.3 Licensing Deals 95 8.3.1 Molecule Type 97 8.3.2 Mechanism of Action 97 8.4 Co-development Deals 100 8.4.1 Mechanism of Action 101 8.5 First-in-Class Programs Not Involved in Licensing or Co-Development Deals 103
9 Appendix 106 JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
9.1 Abbreviations 106 9.2 References 108 9.3 Contact Us 121 9.4 Disclaimer 121 List Of Tables Table 1: Definition of the Stages of Disability in Hoehn and Yahr Scale, 1967 21 Table 2: Evaluation of Disability by Unified Parkinson Disease Rating Scale, 2013 22 List Of Figures Figure 1: Innovation Trends in Product Approvals, 19872013 6 Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 20062013 8 Figure 3: Indirect and Direct Pathways in Basal Ganglia, 2014 15 Figure 4: Molecular Targets of Marketed Products, 2014 30 Figure 5: Efficacy and Safety Heat Map for Marketed Products, Part 1 31 Figure 6: Efficacy and Safety Heat Map for Marketed Products, Part 2 32 Figure 7: Treatment Algorithm of Parkinsons Disease, 2010 34 Figure 8: Treatment Algorithm of Advanced Parkinsons Disease, 2010 35 Figure 9: Developmental Pipeline Overview 39 Figure 10: Breakdown of Molecular Target Family 40 Figure 11: Molecular Target Category Comparison, Pipeline and Marketed Products 42 JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
Figure 12: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets 43 Figure 13: Parkinsons Disease, Global, Pipeline, First-in-class Products in the Pipeline, Part 1/2, 2014 44 Figure 14: Parkinsons Disease, Global, Pipeline, First-in-class Products in the Pipeline, Part-2 45 Figure 15: Signaling Networks of Functional Families in PD 49 Figure 16: Tabular Representation of the Parkinsons Disease-related Processes First-in-Class Targets, Familial Mutants and Susceptibility Genes 50 Figure 17: First-in-Class Molecular Target Analysis Matrix (Part 1) 52 Figure 18: First-in-Class Molecular Target Analysis Matrix (Part 2) 53 Figure 19: Preclinical Evidence for -synuclein as a Therapeutic Target 56 Figure 20: Pipeline Programs Targeting -synuclein 57 Figure 21: Data and Evidence for Leucine-Rich Repeat Kinase 2 as a Therapeutic Target 59 Figure 22: Pipeline Programs Targeting LRRK2 60 Figure 23: Data and Evidence for Glial Cell-derived Neurotrophic Factor as a Therapeutic Target 62 Figure 24: Pipeline Programs Targeting Glial-cell Derived Neurotrophic Factor 63 Figure 25: Data and Evidence for Progranulin as a Therapeutic Target 65 Figure 26: Pipeline Programs Targeting Progranulin 65 Figure 27: Data and Evidence for Cerebral Dopamine Neurotrophic Factor as a Therapeutic Target 67 Figure 28: Pipeline Programs Targeting Cerebral Dopamine Neurotrophic Factor 67 JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
Figure 29: Data and Evidence for Mesencephalic Astrocyte-Derived Neurotrophic Factor as a Therapeutic Target 69 Figure 30: Pipeline Programs Targeting Mesencephalic Astrocyte-Derived Neurotrophic Factor 69 Figure 31: Parkinsons Disease, Global, First-in-Class Tyrosine Receptor Kinase B 72 Figure 32: Pipeline Programs Targeting Tyrosine Receptor Kinase B 73 Figure 33: Data and Evidence for Metabotropic Glutamate Receptor 4 as a Therapeutic Target 74 Figure 34: Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 74 Figure 35: Data and Evidence for Metabotropic Glutamate Receptor 8 as a Therapeutic Target 76 Figure 36: Pipeline Programs Targeting Metabotropic Glutamate Receptor 8 76 Figure 37: Data and Evidence for C-jun-N-Terminal Kinases as a Therapeutic Target 78 Figure 38: Pipeline Programs Targeting C-jun-N-Terminal Kinases 78 Figure 39: Data and Evidence for DJ-1 as a Therapeutic Target 80 Figure 40: Pipeline Programs Targeting DJ-1 80 Figure 41: Data and Evidence for Reactive Oxygen Species as a Therapeutic Target 82 Figure 42: Pipeline Programs Targeting Reactive Oxygen Species 82 Figure 43: Data and Evidence for Heat Shock Transcription Factor 1 as a Therapeutic Target 84 Figure 44: Pipeline Programs Targeting Heat Shock Transcription Factor 1 84 Figure 45: Data and Evidence for Heat Shock Protein 90 as a Therapeutic Target 86 Figure 46: Pipeline Programs Targeting Heat Shock Protein 90 86 JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
Figure 47: Data and Evidence for Growth Hormone Secretagogue Receptor as a Therapeutic target 88 Figure 48: Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 88 Figure 49: Data and Evidence for Protein phosphatase 2A as a Therapeutic Target 89 Figure 50: Pipeline Programs Targeting Protein Phosphatase 2A 89 Figure 51: Data and Evidence for Cytochrome P450 2D6 as a Therapeutic Target 91 Figure 52: Pipeline Programs Targeting Cytochrome P450 2D6 91 Figure 53: Industry Wide Deals by Stage of Development, 20062014 93 Figure 54: Industry Licensing Deal Values by Stage of Development, 20062014 94 Figure 55: Licensing Deals, 20062014 96 Figure 56: Regional Network of Licensing Deals, 20062014 97 Figure 57: Licensing Deals by Molecule Type and Phase, 20062014 97 Figure 58: Licensing Deals by Target, 20062014 98 Figure 59: Summary of Licensing Deals, 20062014 99 Figure 60: Co-Development Deals, 20062014 100 Figure 61: Regional Network of Co-Development Deals, 20062014 101 Figure 62: Co-Development Deals by Target, 20062014 101 Figure 63: Summary of Co-Development Deals, 20062014 102 Figure 64: First-in-class Programs with no Recorded Prior Deal Involvement, 20062014 (Part 1) 104
JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
Figure 65: First-in-class Programs with no Recorded Prior Deal Involvement, 20062014 (Part 2) 105 Product Price :
License Type
Price
$6995
Site Licence
$13990
15Enterprise Wide Licence
$20985
Related reports:
Invion Limited (IVX) - Financial and Strategic SWOT Analysis Review Medicrea International SA (ALMED) - Financial and Strategic SWOT Analysis Review Pacific Hospital Supply Co., Ltd. (4126) - Financial and Strategic SWOT Analysis Review Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review Raysearch Laboratories AB (RAY B) - Financial and Strategic SWOT Analysis Review JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/
AuthentiDate Holding Corporation (ADAT) - Financial and Strategic SWOT Analysis Review Digirad Corporation (DRAD) - Financial and Strategic SWOT Analysis Review BB Biotech AG (BION) - Financial and Strategic SWOT Analysis Review Ortivus AB (ORTI B) - Financial and Strategic SWOT Analysis Review Healthcare and Medical Market Research
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB
Market Research:JSB market research is a leading player in the market of research report distribution. It is one-stop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on “Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation� http://www.jsbmarketresearch.com/healthcare-medical/r-frontier-pharmaparkinsons-disease-identifying-and-commercializing-first-in-class-innovation151420
JSB Market Research Pvt. Ltd.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/